OneVentures is one of Australia’s leading venture capital firms, with over $500 million in funds under management.


Venture Capital

OneVentures

Managing Partners

Jill started her career in corporate tax, ultimately having decided to transition into commercial accounting. She is essential for critical business functions and provides financial controlling as part of the  F&O team. 
She is an experienced and dedicated finance professional, also providing leadership and administrative support to keep the office running smoothly.
Jill is passionate about her 3 kids and enjoys keeping active and fit. She also likes cooking, art and hopes to one day start horse riding again… literally getting back on the horse.
Jill looks after the finance function for the OneVentures corporate entities, including financial accounting, taxation, management accounting and corporate secretarial.
She also supports Risk Management in the firm, looking after many internal controls,   insurances for the business and provides assistance to the Risk Management Committee.
She oversees the outsourced IT support function and assists with HR administration (onboarding, offboarding, employment contracts).

Jill Allen

Matt Lewin

Lu Li

Kate joins [OneVentures](/org/oneventures) from Ireland, before moving to Australia she qualified as a Chartered Accountant with PwC, Dublin. She worked in the Deals department in Business Restructuring Services and spent some time at KKR, working within their private credit arm.
 
Kate has a Bachelor of Business Studies degree with a major in Accounting and Finance from the University of Limerick and is a member of the Institute of Chartered Accountants Ireland and the Irish Australian Chamber of Commerce. She loves to travel and cook.

Kate Madden

Lenny Zeng

Justin Lai

Heather Maini

Shawn Li

Matt Sinnamon

Bernard has experience in the private equity, investment banking and audit professional services industry. He started his career at [KPMG](/org/kpmg) in Sydney where he initially qualified as a Chartered Accountant. 

He then spent several years working for Catalyst Investment, a private equity manager in Sydney, before moving to London and working for the UK based private equity firm [BC Partners](/org/bc-partners). 

Upon returning to Sydney he spent some time at Macquarie Investment Management in a financial control function. 

Bernard has a Bachelor of Commerce degree from the University of New South Wales and is a member of the Institute of Chartered Accountants in Australia and New Zealand.

Bernie Chin

John brings almost 20 years’ global life science experience across operational, venture capital and investment banking roles.  

Most recently John held the role of CFO at Elastagen, an innovative Australian medical device company, until it was sold to [Allergan](/org/allergan), a global medical aesthetics company. The deal was recognised by the AIC as the Best Venture Capital Investment of 2018. Post-closing, John continued to oversee the integration of Elastagen’s clinical programs at [Allergan](/org/allergan) as Director R&D, and latterly as a consultant.   

During his tenure at Elastagen and [Allergan](/org/allergan), John had a broad remit that spanned finance, corporate development and clinical functions, and was intimately involved in internationalizing the business through to its successful exit. As CFO, John led the Company’s fund-raising efforts including the Series B round. He was also heavily involved in the design and execution of the Company’s two clinical studies conducted in the UK.  

Prior to Elastagen, Dr Westwater spent eight years at Nomura Phase4 Ventures in London, investing in early to mid-stage life sciences companies primarily in the US and Europe. John started his career in investment banking with Morgan Stanley where he spent over four years in their Corporate Finance and Mergers, Acquisitions and Restructuring Department (MARD) teams, advising pre-IPO to blue-chip healthcare multinationals on various capital raisings, divestitures and acquisitions.   

At different times in his career, John has also been an independent healthcare consultant, providing strategic advice to various companies through the years.  

Dr Westwater holds a PhD and a BSc (Hons) in Biochemistry from Heriot Watt University in the UK with the first year of his PhD studies spent at Dundee University. He is also a recipient of the Watt Club Medal.  

John Westwater

Nick has over 13 years of debt experience both in direct lending and advisory, in Europe and Australia. 

Prior to joining [OneVentures](/org/oneventures), Nick was based in the UK and was a Principal at [Kreos Capital](/org/kreos-capital), Europe’s largest growth debt fund. His experience there covered deal origination, execution and portfolio management for a significant number of transactions across European markets. He has wider sector experience across technology sub-sectors including FinTech, software, cyber security, hardware, e-commerce/DTC, AdTech and life science, investing in both private and public companies.

Prior to this, Nick was a Manager at [KPMG](/org/kpmg) in London within the Debt Advisory team, where he was involved in managing and advising on a range of debt transaction from mid-market to large cap. Transaction experience covered leveraged finance, corporate refinancing, capital market issuance and strategic financing advice. 

Nick holds an BSc (Hons) in Management from UMIST, UK. He is also an Associate member (AMCT) of the Association of Corporate Treasurers in the UK. He is a keen skier and loves to travel the world.

Nick Gainsley

Sarah is responsible for sourcing life sciences companies and actively shaping their future. She applies her global executional experience and entrepreneurial passion to nurture their success. Her enterprise level leadership experience has been forged over 20 years in a wide spectrum of organisations, including start-up, private companies, ASX and NASDAQ-listed companies, a multi-national pharmaceutical company and university research organisations. 

Prior to [OneVentures](/org/oneventures), she was the Asian Business Development lead for Shire Pharmaceuticals (now Takeda), a global specialty pharmaceutical company. Sarah identified technologies and developed collaborations across Japan, Korea, Australia, New Zealand, Singapore and Taiwan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015.   

Sarah has held senior management roles at Progen Pharmaceuticals, [The University of Queensland](/org/the-university-of-queensland)’s QAAFI institute, Beef CRC and Pyxis Genomics. From 2011-2017 she led the development of the new UQ QAAFI research institute from 32 people to 450 people and a financially profitable position within 5 years. This included leading the negotiation of a complex $70+M staff transfer and research agreement for QAAFI between the University of Queensland and the Queensland Government. In 2012, Sarah spearheaded the IP asset assignment and company wind-up of 20 year $168M Beef Co-operative Research Centre, involving five universities across five state jurisdictions, MLA, CSIRO and Meat and Lamb NZ and pastoral companies. At Progen Pharmaceuticals, Sarah worked collaboratively with the CEO and CFO over several years to secure a total financing of ~$125M via five capital raisings for oncology drug development, and in 2008 led the $22M acquisition of an oncology drug discovery company.   

Sarah has a strong understanding of the pharmaceutical, medical device and healthcare industries including key inflexion points, intellectual property, regulatory and reimbursement strategies, business development options and strategic product management. She combines this with the ability to understand scientific information quickly and build credibility with technical experts and industry players. She is passionate about commercialising new technologies, and has the strategic vision and positive energy to deliver under tight timeframes in a team environment.  

Sarah is a graduate of the Australian Institute of Company Directors (GAICD) and currently holds directorships with Kira Biotech, QAAFI Advisory Board and Life Sciences Queensland. She holds Bachelor level science qualifications from the University of Queensland and a Masters from Cornell University and has completed a postgraduate course at Harvard Business School focusing on negotiation and decision making.  

Sarah Meibusch

Maria Baas is the Investment Relations Director at [OneVentures](/org/oneventures). She is responsible for developing, managing investor relationships and implementing Investor Relations strategy and helping to build out the firm’s Investor Relations capability in the Australian market. 

Maria joined the team from [Macquarie Group](/org/macquarie-group) where she was developing strategic relationships with external stakeholders in the Corporate and Asset Finance division. Prior to that Maria worked at UBS Asset Management where she was responsible for key client relationship management and institutional business development across industry super funds, insurance firms, large corporates and consultants. Maria also held various roles in financial planning and funds management with AMP Capital and AMP Limited more broadly. She started her career in HNW boutique wealth management firm as the Client Relationship Manager. 

Maria holds a Bachelors Degree in HR and Industrial Relations from the [University of Sydney](/org/university-of-sydney). Additionally, she has completed a Graduate Certificate of Finance at [Macquarie University](/org/macquarie-university) and a Diploma of Financial Planning.

Maria Baas

Dr Michelle Deaker is a Founding Partner & Managing Director of [OneVentures](/org/oneventures) and has been primarily responsible for the foundation of [OneVentures](/org/oneventures) firm and capital raisings of [OneVentures](/org/oneventures) Funds. The firm now has almost $400M in funds under management. Michelle serves on the investment committee of [OneVentures](/org/oneventures) three main Funds, leads the technology practice within the firm and is responsible for investor relations managing the supervisory boards of [OneVentures](/org/oneventures) funds.
Michelle has over 20 years experience in the development of high growth technology companies in Australia and the US, has served on the boards of large and small listed and unlisted companies and has a strong background in Australian R&D and expertise in global business expansion. She has negotiated technology transfer contracts with research institutions; established financing syndicates with Australian, Asian and US investors; chaired the boards of several high growth companies; supported early breakthrough commercial contracts; leveraged her extensive networks for the benefit of [OneVentures](/org/oneventures) companies; and negotiated both financing and exit transactions.

Michelle established [OneVentures](/org/oneventures) in late 2006, coming into the venture capital industry as a successful IT industry business owner, entrepreneur and subsequently angel investor. The Company she founded in 1999, E Com Industries (www.giftvouchers.com), became the leading prepaid card and electronic voucher provider in Australia, servicing over 100 major retail brands including Coles Myer and Woolworths, managing $700m in Australian retail liability and eventually expanding operations into the United Kingdom, South Africa and New Zealand. E Com was acquired by UK publicly listed company, Retail Decisions, in 2005, in a transaction returning to investors 4.6xcapital and an average IRR of 70%. Notably, E Com industries was one of only a handful of Australian companies that successfully migrated the dotcom boom and crash through to a successful outcome for investors. Prior to E Com Industries, Michelle established IT enterprise business, Networks Beyond 2000.

Michelle holds a Bachelor of Science (Honours 1st class), Master of Science and a PhD (Applied Science). She is a member of the Australian Institute of Company Directors and Chief Executive Women (CEW).

Michelle Deaker

Jeannie Joughin

Justine Carzino

Peter Gammell is the current Director at [OneVentures](/org/oneventures). Peter has held various other positions throughout their career, including Chairman of Coates Hire from January 2007 to December 2013, CEO of Seven Group Holdings from January 2010 to December 2013, and Director of Consolidated Media Holdings from January 2009 to December 2012. Prior to their work in media, Gammell was the Managing Director of Australian Capital Equity from January 1988 to December 2013.

Peter Gammell studied at [The University of Edinburgh](/org/the-university-of-edinburgh), where they obtained their Bachelor of Science (B.Sc.) degree.



Peter Gammell

Dan Baker received his B.A. in Biology from [Gettysburg College](/org/gettysburg-college) and his medical degree from the [University of Pennsylvania](/org/university-of-pennsylvania). He completed his medical residency at Hershey Medical Center and fellowship in Rheumatology at the [University of Pennsylvania](/org/university-of-pennsylvania), followed by a research fellowship in Rheumatology at Mass General Hospital. He continued on the faculty of the [University of Pennsylvania](/org/university-of-pennsylvania) for 18 years before joining [Janssen](/org/janssen)/Centocor in 2000. 

As Vice President Immunology R&D at [Janssen](/org/janssen), his responsibilities included the clinical development of Remicade, SIMPONI and STELARA as well as other programs in rheumatology, and dermatology. As Disease Area Stronghold Leader he was responsible for Phase II & III clinical development plans for rheumatology products was responsible for the overall strategy on portfolio in rheumatology/immunology. 

He has authored multiple publications in the field of immunology and has served a co-Lead of RTCure which is an academic/industry collaboration that is sponsored by IMI2 and is searching for tolerogenic therapies for rheumatoid arthritis. 

After his retirement from [Janssen](/org/janssen) in 2019 he has been active in continuing to be involved in bringing therapies to patients by providing scientific advice to drug development organisations. He has taken on the role of CEO of [Kira Biotech](/org/kira-biotech-pty) which is an emerging Australian biotech company targeting treatment of immune system disorders with novel immunomodulatory drugs.


Dan Baker

Roger is a director of OneVentures Pty Ltd, a technology venture capital firm, and is the principal shareholder and director of Eureka Capital Partners, a private investment concern. He is also a director of Illawarra Coke Company, an industrial land development concern. 

Mr Massy-Greene previously served as the Chair of [Ausgrid](/org/ausgrid), [Endeavour Energy](/org/endeavour-energy) and Essential Energy, having been appointed by the NSW government in 2012 to oversee reform of the NSW electricity distribution sector.   

He previously co-founded the ASX 200 company Excel Coal Limited and its predecessor Resource Finance Corporation Ltd, and served as Chair of Excel Coal until its acquisition by [Peabody Energy](/org/peabody-energy) in 2006.   

Mr Massy-Greene serves as Chair of Eureka Benevolent Foundation, a family foundation focused on overcoming socio-economic disadvantage.  He is the President of [Cranbrook School](/org/cranbrook-school) and a director of The Hunger Project in the USA and Australia.  

Roger Massy-Greene

Mr Lewin is Chair of the Board and Investment Committee for OneVentures Pty Ltd. He is a member of the Advisory Board of VGI Partners, a leading global investment firm based in Sydney and New York. Mr Lewin was a founding shareholding and Chair of the Advisory Board of [OneVue](/org/onevue) (ASX: OVH) and was a founding shareholder and Executive Director of Reverse Corp (ASX: REF). Previously, he was a Managing Director of Ord Minnett and member of its Group Management Committee, a Principal of Elysium Capital Partners in London, a Managing Director (Equities) for Merrill Lynch in London after holding several positions in the Equities and Investment Banking divisions of SBC (now UBS) in London and SBC Dominguez Barry (now UBS) in Sydney.

Mr Lewin received a Bachelor of Commerce (First Class Honours) and a Bachelor of Laws (Honours) from University of Queensland. He was a visiting lecturer in business finance at the Queensland Institute of Technology. He received the Baillieu Research award in 1989.

Walter Lewin

Anne-Marie Birkill is a Venture Partner, Director of the Manager, and member of the Investment and Risk Management Committees for [OneVentures](/org/oneventures). She is based in Brisbane, a strong source of technology innovation opportunities.

She has over 30 years’ experience in commercialisation and product development, during which time she has worked with hundreds of early stage technology companies and entrepreneurs as director, senior executive, mentor and business coach. Her interest in the technology sector was forged during 15 years in leadership roles in agri-business companies developing and commercialising new cultivars of ornamental, aquatic, food and forestry plants. Prior to co-founding [OneVentures](/org/oneventures) in 2010, she was CEO of i.lab Incubator Pty Ltd, having previously spent five years in the senior management team at UniQuest. During this period Anne-Marie developed successful programs and networks to assist technology commercialisation, start-up formation and growth, as well as capital raising and exit. She has experience of senior management in listed and unlisted companies and was a Director for energy storage company RedFlow Limited during its successful listing on the ASX (ASX:RFX).  

Anne-Marie was Chair of the Board of Charm Health until September 2017 when she lead the company to an acquisition by the Citadel Group (ASX:CGL). She was Chair of the Board for [OneVentures](/org/oneventures) portfolio company Find-me technologies until October 2019 when the company was acquired by iStaySafe Pty Ltd. She currently serves as Director for [OneVentures](/org/oneventures) portfolio companies iStaySafe and Madorra.   

Her experience and reputation in the technology sector is demonstrated through her active participation in the innovation community, including acting on national, state and university advisory Boards and Groups, and as judge for a number of technology awards programs. She is currently an Industry Fellow with The University of Queensland (UQ) Business School, a director for the Australian Investment Council (AIC) and a member of the Investment Committee for the $80M Advance Queensland Business Development Fund. She has also been invited speaker and presenter at a wide range of events, and is a mentor particularly for other women working in the technology industries. In 2013 she was honoured as one of YWCA Queensland’s 125 Leading Women.   

Her qualifications include a BSc(Hons) from Flinders University and an MBA from The University of Queensland, for which she was admitted to the Dean’s Honour Roll for Academic Excellence. She is a FAIM and a GAICD.  

Anne-Marie Birkill

Nigel recently joined [OneVentures](/org/oneventures) as Operating Partner (Technology). Nigel’s experience encompasses over 16 years in leadership roles, often leading high growth start-ups, and 9 years in strategy consulting. Nigel has been a leader in the digital media, technology and telecommunications industries as CEO of [Vodafone](/org/vodafone) Hutchison Australia, 3 Mobile, and the first Chief Executive of the Fairfax Media digital business. Most recently, Nigel was CEO of Melbourne-based technology scale-up, Message Media, leading the strategy development and execution to rapidly grow via acquisitions, new products and geographic expansion. 

Nigel initially worked at the [Reserve Bank of Australia](/org/reserve-bank-of-australia) and then after completing an MBA at [London Business School](/org/london-business-school) spent five years in strategy consulting with [McKinsey & Company](/org/mckinsey-company). At McKinsey, Nigel worked in the Sydney, New York and London offices predominantly advising financial services, telecommunications, technology and consumer goods clients on strategy and organisational issues.  

After leaving McKinsey, Nigel was involved in the beginning of the digital media revolution in Australia. He built and led the start-up of Fairfax Digital for its first seven years, taking it through to break-even. He led the building of a diverse portfolio of organically grown, joint ventured and acquired digital businesses.

In 2003 Nigel joined Hutchison Telecoms Australia (HTA) as Director of Marketing, Sales and Product for the new 3 Mobile business; building the capabilities and systems, growing and leading the team for customer facing functions of 3. In 2007 he became CEO of HTA and 3 Mobile. As CEO, Nigel lead 3 Mobile through a period of rapid growth and cultural change to become a profitable multi-billion dollar business with industry leading products and a well-regarded brand.  In 2009 he led the merger and integration of 3 with [Vodafone](/org/vodafone), remaining as CEO of the merged entity for its first 3 years.

Nigel then became Senior Telecommunications Advisor to the Managing Director of Hong Kong based CK Hutchison Holdings, one of Asia's most successful global conglomerates. During that time he led the start-up of a pan-European cloud-based telecommunications infrastructure business, Hue (Hutchison Global Enabling Services) based in London. 

In 2013 Nigel joined strategy consultants Port Jackson Partners (PJP) as a Director and shareholder leading strategy projects across a range of industries in Australia, New Zealand, United Arab Emirates and United Kingdom. This included work with CEOs of fast growing digital businesses, digital and technology strategies, media, infrastructure, agriculture and international growth initiatives. 
Nigel joined Message Media in 2017 to scale-up and transform the business from a single region, single product, single shareholder business via a substantial investment in technology, people, new processes and platforms, and acquisitions, culminating in a significant Private Equity investment.

Nigel joined [OneVentures](/org/oneventures) as Venture Partner in April 2019 in a part-time capacity to predominantly to work with our digital and technology-based portfolio businesses. He is also on the board of telecommunications infrastructure start-up Stilmark Telecommunications.
 
Nigel has a first class Honours Degree in Economics from James Cook University and a Masters of Business Administration from [London Business School](/org/london-business-school) (with Distinction). 

Nigel Dews

Dr Paul Kelly is a Founding Partner of [OneVentures](/org/oneventures) and serves on the investment committee of [OneVentures](/org/oneventures)’ three main Funds, chairing the Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm. Paul is currently Chair on the Boards of [OneVentures](/org/oneventures) investee companies [Vaxxas](/org/vaxxas) and Hatchtech and is non-executive director of BiVACOR, and [Clinical Genomics](/org/clinical-genomics). He is also non-executive director of US based Agamatrix Inc.

Paul is an Australian physician and serial biotechnology entrepreneur with over 30 years’ experience in developing and commercialising biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, with a record of achievement in transforming ideas, technologies and products into sustainable successful businesses and delivering strong returns for shareholders and investors as a founder and CEO.
Paul joined the [OneVentures](/org/oneventures) team in 2009, as a co-founder of [OneVentures](/org/oneventures)’ first fund in 2010, after spending 15 years in the UK and USA (mostly in Boston, MA). Paul served as CEO of Gemini Genomics (Nasdaq:GMNI), one of the world’s first clinical genomics companies, which he co-founded in 1995 to discover and commercialise novel gene-based diagnostic and therapeutic targets. At Gemini, Paul as CEO led the company in one of the UK's largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world's leading research institutions and biotechnology and pharmaceutical companies. In 2001, Paul led the company's successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over US$250M. Paul then continued in the US working with local biotech and med-tech entrepreneurs and co-founded Agamatrix, now a leading bio-sensing medical device company with operations across the US and South East Asia, and Atomera (Nasdaq ATMR). He then served as President and CEO of Orchid Cellmark (Nasdaq:ORCH) at that time the world’s leading provider of genetic testing services in both the UK and US. During his tenure he developed and implemented major operational, financial and strategic restructuring growing revenues by over 50% in 2 years from US$40M to $60M per annum and increasing the companies valuation 10 fold.

While in the US Paul also served as President and CEO of Medcenter Solutions, a US based online medical education and pharmaceutical marketing company. 

Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specialising in endocrinology at St Vincent's Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute of Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.

Paul has served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians. He also serves on the UNSW Medicine Dean's Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.

Paul Kelly

The board of directors at OneVentures has a lot of experience in different industries. The Executive Chairman used to work at Invictus Advisory, and the CEO used to work at Seven Group Holdings. Both of them have a lot of experience in different fields, and they are also well-educated. The Director at Consolidated Media Holdings is also experienced and educated.

Board of Directors

About

Team members

Other teams at OneVentures

Leadership Team

CEO and Executive Team

Discover similar companies